Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.
EP: 1.Overview of Immune Checkpoint Inhibitors in NSCLC
EP: 2.A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
EP: 3.First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy
EP: 4.First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON
EP: 5.First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
EP: 6.Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
EP: 7.Key Updates in the Changing NSCLC Treatment Landscape
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.
Read More
